Listen as Dr. Sarina Elmariah explores the comorbidities associated with prurigo nodularis.
Join Dr. Sarina Elmariah as she discusses the challenges in diagnosing prurigo nodularis.
Tune in as Dr. Sarina Elmariah describes the management goals for patients with prurigo nodularis.
Dr. Sarina Elmariah explains the importance of neuroimmune crosstalk in the development of prurigo nodularis.
Join Drs. Sarina Elmariah and Pedro Bastos to explore the full systemic burden of prurigo nodularis, looking beyond the nodules to discover how real-world evidence for approved biologics can inform treatment decisions and long-term care across diverse patient populations.
Drs. Sarina Elmariah and Pedro Bastos led an engaging ADVENT Industry Hub at EADV 2026 in Vienna, Austria, exploring the full systemic burden of prurigo nodularis (PN) beyond its visible nodules. The session highlighted how real-world evidence for approved biologics can inform treatment decisions and support long-term disease management across diverse patient populations.
An infographic exploring the pathophysiology of prurigo nodularis and the role of type 2 inflammation.
Dr. Sarina Elmariah explores the complex systemic burden of PN, from diverse clinical presentations and delayed diagnosis to the profound impact of itch, sleep disruption, comorbidities, and reduced quality of life.
Dr Lawrence Eichenfield explores the broadening of treatment goals for long-term disease control, highlighting the importance of this approach in atopic dermatitis. Drs Culton, Elmariah, and Hawkes expand the discussion to further examine specific management goals unique to each skin disease (bullous pemphigoid, prurigo nodularis, and chronic spontaneous urticaria).

Dr Jason Hawkes describes the importance of early intervention for patients with uncontrolled skin diseases and the effectiveness of evidence-based management strategies, sharing a patient case and his clinical insights with chronic spontaneous urticaria. Drs Eichenfield, Elmariah, and Culton join to review the burdens faced by patients with atopic dermatitis, prurigo nodularis, and bullous pemphigoid, respectively.
Dr Donna Culton walks through the pathophysiology of type 2 inflammation in inflammatory skin diseases, using bullous pemphigoid as an example. Drs Eichenfield, Elmariah, and Hawkes join to discuss the role of type 2 inflammation across atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, respectively.
This 2-hour educational program delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, bullous pemphigoid, and chronic spontaneous urticaria. It will highlight both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies. Experts will guide the audience through diverse patient cases to illuminate diagnostic nuances and the pathophysiology of each condition. These cases will also highlight the importance of shared decision-making and the broadening of treatment goals beyond symptom control. Dynamic panel discussion and active audience participation will be facilitated through real-time polling and curated Q&A sessions.